Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial

IMPORTANCE: Doses of fingolimod lower than 0.5 mg per day were not investigated during the fingolimod clinical development program. Whether lower doses of fingolimod might retain efficacy with fewer safety risks remains unknown. OBJECTIVE: To evaluate the efficacy and safety of fingolimod, 0.5 mg, a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Neurol
Main Authors: Cree, Bruce A. C., Goldman, Myla D., Corboy, John R., Singer, Barry A., Fox, Edward J., Arnold, Douglas L., Ford, Corey, Weinstock-Guttman, Bianca, Bar-Or, Amit, Mientus, Susanne, Sienkiewicz, Daniel, Zhang, Ying, Karan, Rajesh, Tenenbaum, Nadia
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2021
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7445630/
https://ncbi.nlm.nih.gov/pubmed/32852530
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaneurol.2020.2950
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados